Paliperidone palmitate prolonged release suspension for injection (six monthly)
Indication
Treatment of schizophrenia in adult patients who are clinically stable on 1-monthly or 3-monthly paliperidone palmitate injectable products
Brand:
Byannli
Nice TA:
Commissioning responsibility:
NHS England
PbR excluded:
No
Background
Paliperidone palmitate 6-monthly injection is recommended as a treatment option for the maintenance treatment of schizophrenia in adult patients who are clinically stable on 1-monthly or 3-monthly paliperidone palmitate injectable products:
• where treatment is in line with the recommendations within NICE CG178 for the use of depot or long-acting injectable antipsychotic medication, and
• where treatment is in line with the Lancashire Care Guidance for Prescribing Second Generation Long Acting Antipsychotic Injections.
Recommendation
LSCMMG Recommendation:
Red
Reason for decision:
Specialist medicine